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ess: richeldi.luca@unimSummary Asthma and cystic fibrosis are two respiratory diseases characterized by
chronic inflammation, leading to remodelling of the airways. Macrolides are widely
used antibiotics, with a peculiar anti-inflammatory effect. On the basis of the
methodologies used by the Cochrane collaboration, this review discusses the
evidence for their long-term use as anti-inflammatory agents in these two diseases.
Three randomized-controlled trials (RCTs) were identified for both asthma and cystic
fibrosis. A positive effect of macrolides on reducing eosinophil numbers and markers
of eosinophilic inflammation was demonstrated in patients with asthma. Data on
cystic fibrosis demonstrated an effect on lung function with an increase of 5.4% in
forced vital capacity (FVC) in patients treated with macrolide vs. placebo, but
without a significant effect on FEV1. Side-effects were rare, mild and reversible on
withdrawal of treatment. Although preliminary data from small studies are
promising, the role of macrolides in the treatment of these chronic disorders needs
to be more firmly established with larger, well-designed trials, targeted to
investigate major clinical outcomes.
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Macrolides are widely used in the treatment of
infectious diseases, including respiratory infec-
tions. Erythromycin, one of the first antibiotics in
this class, was discovered more than 50 years ago.1
Newer molecules that have been used widely
include clarithromycin, roxithromycin and azithro-
mycin. Although these drugs were created for their
antibiotic properties, there is increasing evidence
of an anti-inflammatory effect of macrolides. Thised.
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inflammatory diseases, as well as it posing new
questions about their safety with long-term admin-
istration. Several studies have described the
effects of macrolides on inflammatory mediators.
The reduction of expression of adhesion molecules
(endothelin-1,2 ICAM-13), cytokines (interleukin
[IL]-6,4,5 tumour necrosis factor alpha,5 IL-8,6,7 IL-
1b8), and defensins9 have been reported in vitro, as
well as in animal and human models. An inhibitory
effect on the activation of NF-kB by proinflamma-
tory factors was also reported in several cell
types.10,11 A modulating effect of macrolides on
the recruitment of neutrophils,12 and a reduction in
the oxidative burst, have also been reported.3,13
Erythromycin is able to modulate the expression of
eotaxin from human lung fibroblasts, and this
suggests that macrolides may be used in diseases
characterized by recruitment of eosinophils.14 The
use of macrolides for their non-antibiotic proper-
ties has been demonstrated in clinical practice in
diffuse panbronchiolitis. Macrolides have changed
the prognosis of these patients, and their use in
low-doses over the long term correlates with
modulation of the proinflammatory factors in
bronchoalveolar lavage fluid, but not with the
bacteriological findings.8,15,16 This provides
support for the anti-inflammatory activity of these
molecules.
Asthma and cystic fibrosis are two distinct
respiratory disorders, but both are characterized
by chronic inflammation of the airways.17 The
inflammation may be promoted by infectious
agents. Chlamydia pneumoniae may contribute to
inflammation in asthma.18 The role of Pseudomonas
aeruginosa in cystic fibrosis is well established.19
The role of macrolides in therapy for asthma and
cystic fibrosis has been analyzed in two reviews by
the Cochrane Collaboration.20,21 The current evi-
dence in this area is presented in this review.Macrolides in the treatment of asthma
Asthma is characterized by chronic inflammation of
the airways, bronchial hyper-responsiveness and
paroxysmal attacks of wheezing. A genetic predis-
position is believed to favour the clinical presenta-
tion of the disease with modulation by
environmental factors.22 Eosinophils are a major
component of the inflammation of the bronchial
mucosa in asthma.23 Asthma therapy is based on
the use of anti-inflammatory drugs, with the aim of
decreasing airway inflammation and controlling
respiratory symptoms.17 Drugs that are commonlyused for the treatment of asthma are bronchodila-
tors and corticosteroids. More recent therapies
include anti-leukotrienes, for mild to moderate
asthma, and immunosuppressive drugs, which are
only used in people who are severely resistant to
steroids.24
The first study of the use of macrolides in asthma
aimed to show the effect of oleandomycin in the
management of infectious exacerbations of asth-
ma.25 This was followed by the demonstration of a
steroid-sparing effect of troleandomycin,26 which
led to a series of studies aimed at investigating the
possibility of using these antibiotics to reduce
steroid dosage, particularly in patients with severe
asthma.27–32 However, this approach was aban-
doned because of concerns about toxicity and the
recognition that much of the effect attributable to
troleandomycin was due to inhibition of the
metabolism of corticosteroids. Progress in under-
standing the molecular mechanisms underlying
asthma, and interest in a possible role for chronic
pathogens such as C. pneumoniae,18,33 focused
interest in the newer macrolides, which are safer
than the older ones.
The Cochrane review on macrolide therapy in
asthma20 only considered studies reported as
randomized-controlled trials (RCTs). At least one
of the following outcomes had to be reported for
the study to be included in the review: asthma
symptoms (including symptom scores), use of
asthma medicines (including the dose of oral
corticosteroids in steroid-dependent patients),
lung function (including peak expiratory flow
[PEF], forced expiratory volume in 1 s [FEV1] and
thoracic gas volume), non-specific bronchial hyper-
reactivity, number and type of side-effects, and
eosinophil count, eosinophil cationic protein (ECP)
in peripheral blood samples, sputum, or all three.
Twenty-one studies were considered for inclusion in
the systematic review. The reviewers agreed on the
inclusion of five RCTs of macrolide treatment for at
least 4 weeks for the treatment of adults or
children with chronic asthma. We briefly describe
the design and the findings of these RCTs here.
The study by Nelson et al.34 was designed to
assess the ability of troleandomycin to reduce the
daily steroid treatment required for asthma control
and the long-term side-effects of corticosteroids in
patients with asthma requiring daily treatment.
Seventy-five patients, all of whom had severe
persistent asthma with a history of deterioration
of symptoms when steroid dose was tapered, and
were in the fourth group using the 1995 GINA
scoring system,17 were required to discontinue
inhaled medications before enrolling in the study.
They were randomly assigned to two treatment
ARTICLE IN PRESS
Macrolides in the treatment of asthma and cystic fibrosis 3groups: 250mg troleandomycin/methylpredniso-
lone ðn ¼ 37Þ or placebo/methylprednisolone ðn ¼
38Þ: A 25% reduction of the daily dose of theophyl-
line treatment was possible in all participants.
Steroid dose reduction was initiated immediately,
with a 25% reduction in the alternate-day dose, at
intervals of 6 days and, subsequently, 2 weeks.
Eighteen patients failed to complete the 1-year
double-blind treatment (seven in the troleandomy-
cin/methylprednisolone group and 11 in the place-
bo group; P value, not significant). Of the patients
remaining, 17 in the troleandomycin/methylpred-
nisolone group and eight in the placebo group
completed the 2-year period in double blind. The
investigators reported a significant reduction in the
requirement for hospitalization and steroid boosts
in both groups compared with the previous year.
Similar results were reported during the 2-year
follow-up, but no significant difference was ob-
served between the two groups. The authors of the
study remarked that the steroid dose was tapered
only when symptoms were under complete control,
which is why symptom control was less valuable as
an outcome. The mean steroid dose reported in the
placebo group during the year preceding the study
was significantly higher than that in the troleando-
mycin/methylprednisolone group. Despite a signifi-
cant reduction in the lowest stable dose of
corticosteroids in both groups, neither the 1-year
nor the 2-year reduction in steroid dose was
significantly different in the two groups. Eosinophil
counts were significantly increased at the time of
the 1-year evaluation in both groups. The dual-
photon densitometry of the L2-4 vertebrae showed
a mean decline in bone density in both groups
during the first and second years of treatment, but
the change was significant only in the troleando-
mycin/methylprednisolone group (1 year: P ¼ 0:01;
2 years: P ¼ 0:001). Furthermore, patients treated
with the macrolide showed an increase in fasting
blood sugar, an increase in mean cholesterol level
and a decrease in IgG level. Some of the adverse
effects of troleandomycin may reflect its action to
inhibit steroid metabolism. Despite the significant
reduction in the lowest stable dose of corticoster-
oids, the detrimental side-effects associated with
troleandomycin overweighed the reduction in
steroid dose.
The study by Kamada et al.35 aimed to assess the
efficacy and safety of low-dose troleandomycin in
children with severe, steroid-requiring asthma.
Nineteen patients, aged 6–17 years, were enrolled.
All had reversible obstructive airways disease
according to the American Thoracic Society’s
(ATS) 1987 criteria,36 and all required prednisone
at a daily dose of at least 20mg (severe persistentasthma and in the fourth group of the GINA 1995
scoring system17). During the study, all patients
used inhaled corticosteroids. The patients were
randomly assigned to three treatment groups:
250mg troleandomycin/methylprednisolone once
daily ðn ¼ 6Þ; 250mg troleandomycin/prednisolone
once daily ðn ¼ 8Þ or once daily placebo/methyl-
prednisolone ðn ¼ 5Þ: Randomization was stratified
according to the severity of asthma. After a single-
blind run-in period of at least 1 week, patients
were randomly assigned to receive one of the three
treatments in a double-blind fashion. Steroid doses
were tapered to achieve dosing on every other day,
or a 50% reduction during the first 2 weeks. There
was a significant difference in height between
patients in the troleandomycin/methylpredniso-
lone and placebo/methylprednisolone groups at
baseline. The troleandomycin/methylprednisolone
group also had higher symptom scores and a higher
steroid requirement during the baseline period.
Among the 19 patients enrolled, two were discon-
tinued, both from the troleandomycin/predniso-
lone group: one because of failure to maintain
adequate lung function after 8 weeks of treatment
(data from this patient were included in the
analysis because a follow-up evaluation was ob-
tained before termination) and one after 3 weeks
of treatment because of an elevation of liver
enzymes that necessitated discontinuation of the
antibiotic. A significant reduction in glucocorticoid
dosage was recorded in all three groups: the
maximum tolerated reduction was 8076% in
the troleandomycin/methylprednisolone group
ðPo0:001Þ; 5578% ðPo0:001Þ in the troleandomy-
cin/prednisolone group and 44714% ðP ¼ 0:04Þ in
the placebo/methylprednisolone group. A signifi-
cant difference between groups was found only
between the troleandomycin/methylprednisolone
group and the placebo/methylprednisolone group.
No significant difference was reported for days of
supplemental prednisolone for exacerbations. The
symptom score was reduced by nearly 50% in
patients receiving troleandomycin/methylpredni-
solone ðP ¼ 0:02Þ; but there was no significant
difference in the other two groups. Values of
pulmonary function tests were slightly reduced in
all groups, with a significant reduction of pre-
bronchodilator FEV1 in the troleandomycin/predni-
solone group ðP ¼ 0:02Þ: A patient in the
troleandomycin/methylprednisolone group showed
a mild elevation of liver enzymes, which resolved
spontaneously without discontinuation of the
treatment. A patient in the troleandomycin/
prednisolone group demonstrated a marked devel-
opment of striae on the arms and trunk. No
significant alterations of serum and urine cortisol
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crease was observed in the placebo/methylpredni-
solone group. A slight decrease in bone density was
observed in the two groups receiving troleandomy-
cin. Despite the absence of a prednisolone-only
control group and the low number of participants,
the authors concluded that it was not possible to
improve lung function while tapering steroid dose.
The goal, they stated, was to keep the same levels
of lung function while reducing the dose of steroids
and without encountering severe adverse effects.
The studies on troleandomycin highlighted the
fact that most of the effects of this macrolide in
patients with asthma was due to the inhibition of
the metabolism of corticosteroids. Unfortunately,
this same mechanism was responsible for the higher
proportion of steroid-related side-effects in the
population treated with troleandomycin. Never-
theless, the concept of macrolides as a class of
drugs with effect other than antibiotic was estab-
lished, and instigated a series of studies targeted to
investigate an anti-inflammatory effect of new
macrolides, designed to be well-tolerated and to
have a lower incidence of side-effects.
The study by Shoji et al.37 was designed to
investigate the effects of roxithromycin on (1)
airway responsiveness in the sulpyrine provocation
test, (2) aspirin-induced urinary excretion of
leukotriene E4, and (3) eosinophilic inflammation.
The study enrolled 14 patients who were non-
smokers with a clinical history of aspirin-intolerant
asthma, a positive sulpyrine, lysine aspirin provo-
cation test, or both, and a diagnosis of mild or
moderate asthma according to ATS (1987) criter-
ia.36 All were in stable condition and free of
symptoms of respiratory infection from at least 6
weeks. All of the patients were classified in the first
group (intermittent asthma) of the GINA scoring
system.17 Patients were randomly assigned to two
groups: roxithromycin (150mg twice a day) or
placebo (twice a day), both for 8 weeks. FEV1,
FVC, and blood analyses were carried out at the
beginning and end of the period. After a 4-week
washout period, the participants were crossed over
to receive the alternative treatment for 8 weeks.
All patients underwent a double-blind sulpyrine
provocation test after each 8-week treatment
period with either roxithromycin or placebo. A
spirometric test was carried out before and 5, 10
and 15min after inhalation of sulpyrine. Urinary
levels of leukotriene E4 were measured and the
provocation test carried out before and after the
treatment with the macrolide. A symptom score
(including four steps of symptom severity) was
recorded every week by physicians. All of the PC20
values obtained were logarithmically transformedbefore analysis, and all the summary statistics were
expressed as mean and standard deviation. Symp-
tom scores decreased significantly after roxithro-
mycin treatment (1.6370.4 vs. 0.870.7; Po0:05).
No participant worsened. No significant difference
between roxithromycin and placebo groups was
observed for lung function, for the PC20 values for
provocation test or for urinary leukotriene E4
levels. Mean ECP and eosinophil counts, both in
serum and in sputum, were significantly decreased
after 8 weeks of treatment with the antibiotic
(blood eosinophils: Po0:01; serum eosinophils and
ECP, sputum ECP: Po0:05). No adverse effects
were reported. The investigators concluded that
roxithromycin produces an anti-inflammatory ef-
fect associated with reduced eosinophil infiltration
in patients with aspirin-intolerant asthma.
A study by Amayasu et al.38 was designed to
evaluate the effect of clarithromycin on bronchial
hyper-responsiveness and eosinophilic inflamma-
tion in patients with allergy-induced asthma.
Seventeen patients with allergy-induced asthma
(according to the ATS 1987 criteria36) were enrolled
in the study. On the basis of current treatment,
patients were classified as having intermittent
asthma according to GINA 1995 recommenda-
tions,17 although there was no clear indication
about frequency or severity of asthmatic symp-
toms. Patients were excluded from the study if
there was evidence of a viral infection in the 6
weeks before the study or if patients were on
treatment with drugs other than beta-agonists,
anti-asthmatic drugs or clarithromycin. Patients
were randomly assigned to two treatment groups:
clarithromycin (200mg twice a day) or placebo
(twice a day) for 8 weeks. Blood samples for cell
counts and serum ECP measurements were col-
lected before and after the 8-week period, as well
as were sputum. A methacholine provocation test
was carried out after the 8 weeks, and lung
function was measured 5, 10, and 15min before
and after the provocation test. A crossover period
followed, with the same interventions. A symptom
score was assessed weekly using a 4-point scale.
Fifteen of the 17 patients had an improvement in
their symptom score, whereas two reported no
improvement. The symptom score decreased sig-
nificantly after treatment with clarithromycin
(1.670.4 vs. 0.870.7; Po0:05). Blood and sputum
eosinophil counts and serum and sputum ECP levels
were also decreased significantly by clarithromycin
treatment. For blood eosinophils, the mean values
were 46.376.9 before vs. 12.072.4 104/mL
after clarithromycin ðPo0:1Þ; for sputum eosino-
phils, mean values were 90732 before vs. 1176
ðPo0:05Þ  104=mL after clarithromycin and, for
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and after clarithromycin were 15.277.3 vs.
3.771.5mg/L and 1.770.9 vs. 0.470.1mg/L,
respectively ðPo0:05Þ: However, the study failed
to demonstrate an improvement in lung function
with the macrolide. PC20 methacholine was higher
in the clarithromycin group than in the placebo
group (mean log-PC20 methacholine: 2.970.6 in
the clarithromycin group; 2.670.5 in the placebo
group; Po0:01). No association was found between
increased PC20 methacholine and ECP levels. No
adverse reactions were reported during the treat-
ment with clarithromycin. The investigators con-
cluded that clarithromycin has anti-bacterial and
anti-inflammatory activity, which is associated with
reduced eosinophil infiltration and an improvement
of symptoms and hyperresponsiveness.
Black et al.39 conducted a multicentre, multi-
national study on the effect of roxithromycin in
asthmatic patients with serological evidence of C.
pneumoniae infection (demonstrated by IgG and
IgA titers). Two hundred and thirty-two patients,
aged 18–60 years, with a defined diagnosis of
asthma and FEV1 50–90% of predicted, were
enrolled in four countries: Australia, New Zealand,
Italy and Argentina. Because the report of the study
lacked a clear description of symptoms or drugs
needed for each patient, classification according to
GINA score17 was not possible. Patients were
randomly assigned to two treatment groups:
roxithromycin (150mg twice a day) or placebo,
both for 6 weeks. Outcome measures were as
follows: symptoms and morning and evening PEF
values were recorded during treatment and for 6
months after treatment. The asthma quality of life
questionnaire (AQLQ) was administered at rando-
mization and at weeks 2, 6, 12 and 24 after the
beginning of treatment. At the same time, spiro-
metric tests were carried out. Thirteen patients
randomized to treatment withdrew from the study.
Of the remaining 219 patients, 105 were in the
roxythromycin group and 114 were in the placebo
group. No significant differences between the two
groups were recorded for patient characteristics or
lung function tests. At the end of the 6-week
treatment, the increase in the mean values of PEF
was significantly higher in the treated group only
for the evening values (morning PEF: 17 L/min;
evening PEF: 18 L/min), compared with the placebo
group (morning PEF: 7 L/min; Po0:05; evening PEF:
3 L/min; Po0:03). Three months after treatment, a
non-significant increase in PEF values was still
present in the treated group; at the same time
point, the symptom score had decreased by 33% in
the treated group, but only by 22% in the placebo
group. In the 149 Australian patients, both morningand evening PEF values were significantly increased
in the treated group (20 L/min) compared with the
placebo group (not significant; specific value not
reported). In the subgroup analysis, the increase in
PEF values 3 months after treatment was higher in
the treated group than in the placebo group,
although not significant. No significant difference
was recorded for the daytime and night-time
symptom scores or for AQLQ results. No difference
was found for rescue medications or for antibody
titers measured during the study. Only mild,
reversible alterations in liver function test results
were recorded in two patients treated with
roxythromycin. The authors concluded that the
(non-significant) trend towards improved pulmon-
ary function test results seen at 3 months after
treatment in the roxithromycin group compared
with the placebo group suggested that the effect of
macrolide therapy on PEF values may be due to an
anti-microbial effect rather than to an anti-
inflammatory effect of the drug, and that the loss
of benefit over time at the end of treatment may be
due to the suppression of C. pneumoniae infection
as opposed to eradication.
Since the time of the Cochrane review, a new
study, by Kraft et al.40 had been published. This is a
double-blind, RCT investigating the effect of the
treatment with clarithromycin on pulmonary func-
tion tests and inflammation in asthmatic patients
with an evidence of infection by M. pneumoniae or
C. pneumoniae. The investigators enrolled 52
asthmatic patients, and, among them, 31 had an
evidence of infection by M. pneumoniae or C.
pneumoniae. The patients were randomized to
clarithromycin 500mg twice a week or placebo
for 6 weeks. The patients are likely to be, for the
most part, moderate persistent asthmatics (Class III
of the GINA guidelines), although this was not
reported as such in the paper. Three patients were
reported as withdrawn, but it was not reported in
which arm of the study they were allocated. In the
14 patients with a positive PCR for an intracellular
pathogen who underwent the treatment with
clarithromycin, a decrease in the expression of IL-
5 in BAL cells was observed by in situ hybridization.
In the same patients, a significant increase of about
200mL ðP ¼ 0:05Þ in the absolute value of the FEV1
was observed. These results suggest a possible
effect of the treatment with macrolides on the
inflammation in asthmatic patients with evidence
of infection by intracellular pathogens, although
this will need to be confirmed with a clearer
demonstration of the infection in a larger cohort of
patients.
In a recent Cochrane review,20 a meta-analysis
was carried out using the data reported in the
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Although there were differences in the two
subgroups of patients (allergic and aspirin-intoler-
ant) and the choice of drugs (roxithromycin and
clarithromycin), the use of the same markers of
inflammation enabled the combination of the data.
Both studies showed an improvement in symptom
score and a significant reduction in the markers of
eosinophil inflammation (eosinophil count and ECP
in blood and sputum) (Fig. 1), providing evidence
for a possible anti-inflammatory effect of macro-
lides in patients with asthma. No significant side-
effects were reported. The trial reported by Black
et al.39 is by far the largest study looking at the
effects of macrolides in chronic asthma but,
because of differences in the study design, it wasFigure 1 Meta-analysis of two RCTs37,38 on the use of macro
macrolides in reducing markers of eosinophil inflammation (e
in blood and sputum.not combined with the data from the studies by
Shoji et al.37 and Amaysu et al.38Macrolides in the treatment of cystic
fibrosis
Macrolides have also been assessed for a possible
anti-inflammatory effect in cystic fibrosis, the most
common inherited disease in Europeans and people
of European origin. Cystic fibrosis is caused by a
single mutation in the cystic fibrosis transmem-
brane conductance regulator gene, which leads to
abnormalities in the transport of salt and water
across the surface of epithelia. More than 1000lides in intermittent asthma. A clear, positive effect of
osinophil cationic protein and eosinophil count) is present
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least five functional correlates of the chloride
channel protein have been determined. Malfunc-
tioning of salt and water transport is evident in a
number of organs, but lung involvement is the most
frequent cause of disability and death. The defect
is thought to result in dehydrated airway secretions
and an inability to clear these secretions. An
abnormal inflammatory response accounts for the
lung infection and damage that are characteristic
of this disease.41 Recurrent bacterial infections
lead to a cycle of lung injury and progressive
damage, favouring new infections and the forma-
tion of bronchiectasis all over the bronchial tree.
Despite progress in understanding the pathogenesis
of cystic fibrosis, and the use of drugs such as
bronchodilators, DNase, and steroids have only
improved survival, and measures such as phy-
siotherapy and treatment of infectious exacerba-
tions remain important in the management of
cystic fibrosis. Typical organisms involved in re-
spiratory infections include Staphylococcus aureus
and, in a later stage, P. aeruginosa. The treatment
of P. aeruginosa infection is not free of problems
because of the need for intravenous administration
in most cases and the increasing resistance of the
bacteria to antibiotics after prolonged administra-
tion.
Macrolides are not directly active against P.
aeruginosa. However, recent evidence has shown
that macrolides can be helpful in reducing the
secretion of virulence factors by P. aeruginosa, as
observed in people with diffuse panbronchiolitis.
Such virulence factors include a mucoid biofilm that
protects P. aeruginosa from antibiotics and the host
defenses, favouring colonization of the bronchial
epithelium and the persistence of the infection and
of the inflammatory response. As the long-term use
of macrolides has a beneficial effect on outcome in
patients with diffuse panbronchiolitis, similar ef-
fects of macrolides in the treatment of cystic
fibrosis were hypothesized. An anti-inflammatory
effect of macrolides could be expected, given their
unique activity against the virulence factors of P.
aeruginosa.19,42
Here, we present the methodology and results of
a review of the literature on the use of macrolides
in patients with cystic fibrosis.21 For this review,
trials were included only if a diagnosis of cystic
fibrosis was firmly established. Quasi-randomized
designs were accepted if there was sufficient
evidence that the intervention and control groups
were similar at baseline, as were crossover trials
for short-term outcomes only. Double-blinded trials
were preferred, but single-blind and open studies
were also reviewed for possible inclusion.Two hypotheses were tested: (1) macrolides
improve clinical status compared with placebo, no
placebo, or another antibiotics; and (2) macrolides
do not have unacceptable adverse effects. Types of
intervention included short- and long-term (X12
months) use of macrolides compared with control
participants who received placebo, another anti-
biotic class, another macrolide or the same macro-
lide at a different dose. Primary outcomes were
number of days as a hospital inpatient, lung
function, age at which the participant acquired
long-term P. aeruginosa infection (as defined by
more than two positive respiratory cultures per
year) or acquisition of P. aeruginosa during the
study period, number of additional courses of
intravenous antibiotics, adverse effects of antibio-
tic treatment and improvement in survival. Rele-
vant studies were identified from the cystic fibrosis
trials register using the terms antibiotics,
erythromycin, azithromycin, clarithromycin and
roxithromycin. The register is compiled from
electronic searches of the Cochrane central regis-
ter of controlled trials, quarterly searches of
MEDLINE, a search of EMBASE to 1995 and the
prospective hand-searching of Paediatric Pulmo-
nology. The results of this search are described
below.
Twelve studies were identified as potentially
eligible for meta-analysis; only two RCTs43,44 were
included in the review.21 Equi et al.43 enrolled 41
children, aged 8–18 years, who were receiving
250mg of azithromycin (500mg if weight
was440 kg) once a day for 6 months. Baseline
characteristics of the placebo and azithromycin
groups were similar. Twenty-one children were
chronically colonized by P. aeruginosa, and 38 of
the 41 children were receiving long-term anti-
Pseudomonas nebulized therapy. Twenty-five chil-
dren were receiving long-term anti-S. aureus
prophylaxis and 12 had grown S. aureus on more
than three respiratory cultures in the past 12
months. Seventeen patients did not grow P.
aeruginosa from the cultures during the treatment
period. This study used a crossover design, which
may be problematic in assessing a therapy with
potentially long-term effects. The study also
demonstrated a significant improvement of the
FEV1 of 5.4% in the azithromycin group, although
the study had originally been powered to detect a
FEV1 difference of 7%.
Wolter et al.44 enrolled 60 adults with cystic
fibrosis, aged 18–44 years, who received 250mg of
azithromycin once a day for 3 months. FEV1%
predicted for the placebo group was 62.3724.8%
(mean7SD), which was significantly greater
than that for the azithromycin group (mean
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men than women, and men were on average
taller and heavier. Fifty-seven participants pro-
vided a sputum sample at baseline. In 47
samples, P. aeruginosa was isolated and, in 24
samples, S. aureus was isolated. The primary
outcome measure was percent change in FEV1
and FVC. The placebo group had a greater decline
of FEV1 (3.671.8%; P ¼ 0:047) and FVC
(5.771.7%; Po0:001). Furthermore, patients
in the macrolide group had fewer courses of
intravenous antibiotics, a significant decline in
C-reactive protein levels, and a higher AQLQ
score compared with patients in the placebo
group.
A published meta-analysis of the results of these
two RCTs after 3 months of treatment showed an
improvement in lung function (mean increase of
5.42% in the FVC in the patients treated with
macrolide vs. placebo, which was statistically
significant but there was no significant effect on
FEV1). Only one of these studies reported an
improvement in clinical status.21 A possible carry
over effect due to the crossover design of the study
by Equi et al.43 was avoided by only including data
from the first arm of the study.
Since the Cochrane Review was published,
another multi-center study has been reported.
Saiman et al.45 studied the effect of low-dose,
long-term administration of azithromycin on the
pulmonary function of patients with cystic fibrosis.
One hundred and eighty-five patients aged 6 years
or more, with evidence of P. aeruginosa infection
and a FEV1 30% of the predicted value or higher,
were randomly assigned to receive 250mg of
azithromycin ðn ¼ 87Þ or placebo ðn ¼ 98Þ 3 days a
week for 168 days. At the end of the treatment
period, the macrolide group showed a significantly
greater increase in FEV1 than did the placebo group
(0.09770.26 L vs. 0.00370.23 L; P ¼ 0:009).
Furthermore, patients treated with azithromycin
had a lower risk of exacerbations and a greater
increase in body weight. A significantly higher
proportion of minor side-effects (especially nausea,
diarrhoea and wheezing) was also reported in this
group.
So far, only three RCTs comparing azithromycin
with placebo to treat chest infections in cystic
fibrosis (a total of 286 individuals studied) have
been published. The trials used different times,
doses and molecules, and the main criteria for
inclusion (especially age, pulmonary function tests,
and microbiology) posed a problem with aggrega-
tion of the data. Although the data from these
studies suggest a positive effect on pulmonary
function and markers of inflammation, larger RCTsare needed to confirm these data before the
routine use of macrolides in patients with cystic
fibrosis can be recommended.Conclusions
This review was undertaken to clarify the body of
evidence for the use of macrolides in two distinct
diseases characterized by chronic inflammation of
the airways. Although asthma and cystic fibrosis are
distinct, published data suggest a potential role for
the long-term administration of macrolides. The
precise role of macrolides in the treatment of
asthma remains unclear because of the quality and
sample size, the heterogeneity of interventions and
the different features of patients enrolled in the
available RCTs. Nevertheless, newer macrolides
were found to be safer and better tolerated than
older ones: no major side-effects were recorded in
three studies,37–39 suggesting that the long-term
use of these drugs is feasible in a clinical setting
without significant risk for the patients. A clear
effect on eosinophil infiltration and on markers of
eosinophil inflammation was observed in the meta-
analysis of two studies,37,38 and this correlated
with improvement of symptoms. Even considering
these results, larger, better-designed RCTs are
needed to fully clarify the role of macrolides in
the treatment of asthma and to recommend their
use in clinical practice.
Despite the promising data on the effect of
macrolides on neutrophil recruitment, the reduc-
tion of virulence factors of P. aeruginosa, and the
similarities with diffuse panbronchiolitis, the role
of macrolide therapy in the treatment of cystic
fibrosis remains unclear. Although the three pub-
lished RCTs43–45 showed some improvement in lung
function, the aggregation of the results is difficult
because of the baseline features of the patients
enrolled, the different regimens used to treat the
patients with macrolides and the different time-
points of the studies. Furthermore, a clear effect
on the clinical status was not demonstrated. Until
the results of further studies are available, the
widespread use of azithromycin in cystic fibrosis
cannot be advocated, and this drug should be
restricted to well-designed, randomized clinical
trials.
Macrolides are a unique class of molecules with
both anti-bacterial and anti-inflammatory effects.
However, if their use in infectious diseases is widely
accepted, their role in the treatment of the
inflammatory component of chronic disorders
needs to be more firmly established.
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 Preliminary data suggest that macrolides
have an anti-inflammatory effect in asthma
and that they may lead to an improvement
in lung function. However, there is insuffi-
cient evidence to make any clear recom-
mendations about their use in the treatment
of asthma.
 Three RCTs on the use of macrolides in cystic
fibrosis have been published. They show
some effect on lung function and symptoms.
However, there is insufficient evidence to
justify the routine use of macrolides in the
treatment of cystic fibrosis.
 In studies to date, the use of macrolide for
weeks to months has been associated with
few adverse effects. These have been mild
and reversible after discontinuing treat-
ment.Research directions
 Further long-term studies are necessary in
asthma and cystic fibrosis. Research is
needed to clarify the mechanisms of action
of these medicines and the relative impor-
tance of anti-inflammatory compared with
anti-microbial effects.References
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